Artemisia annua, Hyb8001r
This website provides information about an established variety of Artemisia annua, Hyb8001r.
The medicinal plant Artemisia annua produces artemisinin, the active ingredient for anti-malaria drugs called Artemisinin Combination Therapies (ACTs).
Malaria is a major global health problem: there were 219 million new cases of malaria in 2017 and an estimated 435,000 malaria-related deaths. The greatest malaria burden is for the African region.
Centre for Novel Agricultural Products, University of York
CNAP is a research centre in the Department of Biology. Our aim is undertake research that benefits society. Read more here.
The CNAP Artemisia Research Project was directed by Professor Ian Graham and was funded by the Bill & Melinda Gates Foundation.
From 2011 – 2018, CNAP worked in partnership with East West Seed International, who were the first to demonstrate field-based A.annua hybrid seed production, confirming the feasibility of sustainable, large-scale seed production and distribution of our hybrids, and substantially reducing the costs of hybrid seed.
Ian Graham, CNAP: "This project demonstrated how world-class, strategic research can be delivered with impact for the benefit of developing countries."
Since 2006, CNAP has been supported by Swiss research institute, Mediplant, who have developed detailed advice about how best to grow A.annua hybrids. Read more here: www.artemisiaf1seed.org/agronomy/